Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma

### Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma

Expert

We at Advanced Medicine In China are proud to have Professor Qiu Luguo as our contracted expert. He provides telemedicine consultations for our international patients and can arrange for them to travel to China through a special fast-track system. Patients can receive treatment in the hospital where Professor Qiu works, under his direct supervision as their attending physician, ensuring comprehensive and professional care throughout the treatment process.

Professor Qiu is renowned in the field of hematologic oncology, particularly for treating patients who have not responded well to standard therapies. His deep expertise and innovative treatment approaches have brought new hope to patients, especially those with complex conditions. Through our services, international patients can not only access cutting-edge treatment recommendations via telemedicine but also come to China to receive the most advanced medical care.

The process is straightforward and efficient. Patients only need to submit the following documents, and our team will assist in arranging everything from teleconsultation to full treatment in China:

1. Pathology report

2. Latest discharge summary

3. Detailed description of the condition

4. History of treatment and its effectiveness

We recommend Professor Qiu for his exceptional achievements and extensive experience, which have provided a wide range of treatment options for countless hematologic cancer patients. His international reputation further affirms his outstanding contributions to the fields of hematology and multiple myeloma.

### Expert Profile

Professor Qiu Luguo is the Director of the Lymphoma Diagnosis and Treatment Center at the Hematology Hospital, Chinese Academy of Medical Sciences, and Director of the Tianjin Cord Blood Hematopoietic Stem Cell Bank. He has long been dedicated to both clinical and basic research in hematologic diseases. Professor Qiu is a recipient of the State Council’s special government allowance and has been recognized as an Outstanding Young and Middle-aged Expert by the National Health Commission of China. As a leading authority in lymphoma and multiple myeloma treatment, he is also a member of several international academic organizations, including the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG).

### Areas of Expertise

Professor Qiu is highly skilled in the diagnosis and treatment of lymphatic system tumors, particularly in the precise diagnosis, stratified treatment, and prognosis evaluation of lymphoma, chronic lymphocytic leukemia, and multiple myeloma. He has also made significant progress in the application of hematopoietic stem cell transplantation technology, offering new treatment options for patients with hematologic diseases.

### Research Contributions and International Recognition

Throughout his 30-plus-year career, Professor Qiu has completed more than 30 national research projects and published nearly 700 papers in leading academic journals, with over 160 of them in SCI-indexed journals. His research achievements have garnered widespread attention in China and have been highly regarded in the international hematology community. He has been invited to speak at numerous international conferences and actively promotes global academic collaboration and exchange.

### Major Research Directions

Professor Qiu’s research focuses on the pathogenesis and precision treatment strategies for lymphatic system tumors. His work spans a broad range of fields, from basic research to clinical applications, covering the diagnosis, prognosis, and personalized treatment of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Additionally, he has conducted in-depth studies on hematopoietic stem cell transplantation and stem cell engineering, striving to develop innovative therapies that improve patient cure rates.

### Publications and Scientific Achievements

Professor Qiu has authored five major medical books, holds five national invention patents, and has received multiple first-place awards for his scientific achievements in China. His groundbreaking work in the genomics of multiple myeloma and chronic lymphocytic leukemia has made significant progress in early diagnosis and targeted treatment of these diseases. His research has not only advanced the treatment of lymphatic system tumors but also set an example for young researchers in the field of hematology.

With his exceptional clinical and research accomplishments, Professor Qiu Luguo has become a key figure in the global hematology community. His contributions have not only brought hope to patients but also laid a solid foundation for future advancements in the treatment of blood diseases. Some of his major publications include:…

1. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283. (IF: 19.456)

2. Indirubin-3′-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. E Bio Medicine. 2022 Apr;78:103950. (IF:11.205)

3. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. (IF: 12.531)

4. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021 May 27;137(21):2890-2901. (IF: 22.133)

5. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021 Aug;35(8):2412-2415. Jan 22. (IF:12.883)

6. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020，136(4):468-479. (IF:16.509)

7. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020,34(2):578-588. (IF:11.528)

8. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018,128(7):2877-2893. (IF:12.87)

9. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017.31(5):123-1135. (IF:11.412)

10. Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med.19(2):182-191. (IF:7.756)

### Online Consultation and Appointment Information

Professor Ke currently offers online video consultation services. Patients can make appointments through the following methods:

WhatsApp: Https://wa.me/+8613717959070 

Wechat：doctors0152

Email: doctor.huang@globecancer.com

#HematologyExpert #MultipleMyeloma #LymphomaTreatment #BloodCancer #StemCellTransplantation #MedicalInnovation #Telemedicine #InternationalHealthcare #AdvancedMedicineInChina #PrecisionMedicine #ProfessorQiuLuguo #CancerResearch #GlobalHealth #PatientCare #Oncology

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Hematological Neoplasms

Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment

Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment

Global Healthcare

In the journey of treating hematologic malignancies, for patients in advanced stages with no standard clinical treatment options, seeking medical care abroad or through remote video consultations has become a pathway to new hope. Through these means, patients can connect with top international experts and gain access to new treatment plans and more options. Leading international specialists not only continuously achieve breakthroughs in treatment technologies but also provide personalized treatment recommendations based on the latest research. Next, we are proud to introduce a highly acclaimed and renowned expert in the fields of hematology and lymphoma from China—Professor Ke Xiaoyan.

### Expert Profile

    **Professor Ke Xiaoyan** is the Chief Physician of the Hematology Department at Peking University Third Hospital and serves as the Lead Expert of the Adult Lymphoma Division at the GoBroad Medical (Hematology) Beijing Research Center. She is also the Deputy Director of the Hematology Department at Peking University Health Science Center. Additionally, she holds the position of Chief Consultant for the Adult Lymphoma Department at Beijing GoBroad-Boren Hospital, where she has trained numerous PhD students, establishing herself as one of China’s top experts in hematologic oncology.

    Professor Ke is highly regarded within the Chinese medical community. She has served as the Chairperson of the Hematology Branch of the Chinese Female Physicians Association and currently holds key positions in several authoritative medical organizations. Her academic background and international reputation have earned her wide recognition in the field of hematologic malignancy treatment.

### Areas of Expertise

    Professor Ke has extensive experience in the standardized treatment of lymphoma, targeted chemotherapy, and both autologous and allogeneic hematopoietic stem cell transplantation. She is at the forefront of international research in treating relapsed and refractory lymphomas through second-generation gene sequencing, targeted therapies, and CAR-T cell immunotherapy. Beyond her clinical expertise, she is a leading figure in the molecular diagnosis of malignant blood diseases and the monitoring of minimal residual disease.

### Research Contributions and International Reputation

    Professor Ke has made remarkable achievements in scientific research as well. She has been the principal investigator in more than 70 international multicenter clinical trials and has published over 300 academic papers, including more than 30 influential SCI papers in top-tier international journals, focusing on cutting-edge research in lymphoma and hematologic malignancies. She has authored and contributed to more than 30 authoritative medical books and received over 40 national research grants, significantly advancing the field of hematology.

    In addition to her research work, Professor Ke serves on the editorial boards of several medical journals, including as Deputy Editor-in-Chief of the **Journal of Leukemia & Lymphoma**. She is also a consulting expert for the Ministry of Health and a key member of the Central Health Consultation Committee. As a leading figure in international hematologic oncology research, her studies encompass the molecular mechanisms of lymphoma, immunotherapy, and stem cell transplantation, enhancing China’s standing in global academic research.

### Main Research Focuses

– Standardized treatment of lymphoma

– Molecular diagnosis of malignant blood diseases and monitoring of minimal residual disease

– Research on autologous peripheral blood stem cell transplantation for malignant blood diseases

– Non-myeloablative transplantation and CAR-T cell therapy for refractory relapsed malignant lymphoma

– Research on B7/CD28 signaling and T-cell immune tolerance mechanisms

– Study of the molecular mechanisms of tumor immunity

### Publications and Research Achievements

Professor Ke Xiaoyan has authored several authoritative books in the field of lymphoma, including **Lymphoma** and **Lymphoma Diagnosis and Treatment Manual**. Her key SCI papers include:

1. **Biological and Clinical Influences of NPM1 in AML Patients with DNMT3A Mutations**, *Cancer Management and Research*, 2018.

2. **Clinical and Biological Implications of IDH1/2 in AML with DNMT3A Mutation**, *Cancer Management and Research*, 2018.

3. **High PD-L1 Expression Predicts Poor Prognosis in Diffuse Large B-cell Lymphoma**, *Annals of Hematology*, 2018.

4. **Molecular Predictors of Post-transplant Survival in Acute Myeloid Leukemia**, *Blood Cancer Journal*, 2017.

5. **High Expression of CPNE3 Predicts Adverse Prognosis in AML**, *Cancer Science*, 2017.

6. **High Expression of ETS2 Predicts Poor Prognosis in AML**, *Journal of Translational Medicine*, 2017.

7. **A Minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 Contributes to Leukemogenesis in t(8;21) AML**, *International Journal of Cancer*, 2017.

### Online Consultation and Appointment Information  

Professor Ke currently offers online video consultation services. Patients can make appointments through the following methods:

WhatsApp: Https://wa.me/+8613717959070 

Wechat：doctors0152

Email: doctor.huang@globecancer.com

#Hematology #LymphomaTreatment #AdvancedCancerCare #InternationalConsultation #CAR_TTherapy #PersonalizedMedicine #ProfessorKeXiaoyan #StemCellTransplantation #CancerResearch #GlobalHealthcare